netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Formulary Chapter 6: Endocrine system - Full Chapter
Chapter Links...
 Details...
06.05.01  Expand sub section  Hypothalamic and anterior pituitary hormones and anti-oestrogens
06.05.01  Expand sub section  Anti-oestrogens
06.05.01  Expand sub section  Anterior pituitary hormones
Tetracosactide (Synacthen®)
(Corticotrophin)
View adult BNF View SPC online View childrens BNF
Formulary
Red
  • Approved formulations include:
    • 250microgram in 1ml injection;
    • 1mg in 1ml depot injection. 

 
 
Choriogonadotropin Alfa (Ovitrelle®)
(Gonadotrophin)
View adult BNF View SPC online View childrens BNF
Formulary

  •   Fertility treatment Red Traffic Light

  •   Hypogonadism Green Traffic Light

 
 
Lutropin Alfa
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
 
Menotrophin (75 units FSH & 75 units LH activity) injection
(Gonadotrophin)
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
 
Pegvisomant (Somavert®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
 
 
SomatrogonBlack Triangle (Ngenla®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
CCG

24mg and 60mg solution for injection in pre-filled pen

 
Link  NICE TA863: Somatrogon for treating growth disturbance in children and young people aged 3 years and over
 
Somatropin (children)
(Growth hormone - children)
View adult BNF View SPC online View childrens BNF
Formulary
Red
  • First line
  • Omnitrope® 5-mg (15-unit) vial (powder with diluent) for use with Omnitrope Pen L® device, 3.3 mg (10 units)/ml, 1.5 ml (5-mg, 15-unit) cartridge & 6.7 mg (20 units)/ml, 1.5 ml (10-mg, 30-unit) cartridge - for use with Omnitrope Pen 5® & Omnitrope Pen 10® devices respectively. 
  • Note: Omnitrope is the least expensive formulation of somatropin and should be used in all de novo paediatric patients where possible. 
  • Second line 
  • Norditropin SimpleXx® 1.5ml cartridges for use in Nordipen® devices - 5mg (15 units), 10mg (30 units) and 15mg (45 units). Note: norditropin is the second least expensive alternative formulation for patients who cannot tolerate omnitrope. 
  • Saizen® 8mg vials (powder with diluent), Saizen® 5.83 mg/ml solution for injection (6mg cartridges), 8 mg/ml solution for injection (12mg and 20mg cartridges) - for use in EasyPod® device (to be used in patients with compliance issues).
  • Third line
  • Genotropin Miniquick® syringes - 0.2mg (0.6 units) 0.8mg (2.4 units) 1.4mg (4.2 units), 0.4mg (1.2 units) 1mg (3 units) 1.6mg (4.8 units) 0.6mg (1.8 units), 1.2mg (3.6 units) 2mg (6 units). To be used for patients when travelling.
  • Zomacton® (needle free presentation) 12 unit (4mg) injection; 1st line: 75% to 85% of total mg usage; 2nd line: 15% to 25% of total mg usage; 3rd line: up to 5% of total mg usage.
 
Link  NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children
 
Somatropin - adults
(Growth hormone - adults)
View adult BNF View SPC online View childrens BNF
Formulary
Red
  • Genotropin® cartridges for use in Genotropin pens - 16 unit (5.3mg) & 36 unit (12mg) in 1ml. 
  • Genotropin Miniquick® syringes - 0.2mg (0.6 units), 0.8mg (2.4 units), 1.4mg (4.2 units) 0.4mg (1.2 units) 1mg (3 units) 1.6mg (4.8 units) 0.6mg (1.8 units) 1.2mg (3.6 units) 2mg (6 units) - to be used for patients when travelling.
 
Link  NICE TA64: Human growth hormone (somatropin) in adults with growth hormone deficiency
 
Follitropin Alfa
(Recombinant human follicle stimulating hormone)
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
 
06.05.01  Expand sub section  Hypothalmic hormones
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Drugs for hospital use only. The responsibility for initiation and monitoring treatment should rest with an appropriate hospital clinician and the drug should be supplied through the hospital throughout the duration of treatment. In some very exceptional circumstances (e.g. due to distance from the hospital, storage, supply or mobility/transport problems) it may be appropriate for the GP to be asked to prescribe a Red drug. This should be negotiated on an individual patient basis and should only be done with the GP’s prior informed agreement where the roles of the GP and hospital services are clearly defined and agreed. The GP should not feel under pressure to prescribe in these circumstances. For all RED drugs automatically added to the formulary in response to a positive NICE TA: Prescribers need to ensure that local Trust new drug governance procedures and pharmacy processes are followed before any prescribing.  

Amber

Drugs initiated by hospital specialist, but where continuing treatment by GPs may be appropriate under a shared care arrangement. The specialist should send the GP a copy of the shared care agreement to sign. The GP should sign the shared care agreement, or indicate they do not want to be part of such an agreement, and return a copy back to the specialist. Shared care guidelines are available or are being developed for most of the drugs listed as Amber. If no shared care guideline is available, the hospital specialist should provide the patient’s GP with sufficient information and support to allow treatment to be continued and managed safely in primary care.  

Green plus

Drugs normally recommended or initiated by a specialist (hospital or GP with an extended role https://www.rcgp.org.uk/gpwer), but can be safely maintained in primary care with very little or no monitoring required. In some cases there may be a further restriction for use outlined - these will be defined in each case. Provision of additional information, or an information leaflet, may be appropriate in some cases to facilitate continuing treatment by GPs.  

Green

Drugs where prescribing by GPs is appropriate. Can be initiated and prescribed in all care settings, and if appropriate, discontinued without recourse to secondary care.  

Black

NOT APPROVED: Drugs that have been considered by NTAG or the NENC ICB Medicines Subcommittee (or other approved body) and are not approved for prescribing within the North East and North Cumbria.   

Brown

UNDER REVIEW: drugs whose current formulary status or RAG status is currently under review.  

Not Recomended

NOT REVIEWED: Drugs that haven not been reviewed yet. This usually means that an application is in progress. These drugs are not normally considered appropriate for prescribing in the North East and North Cumbria until such time that a decision is taken on their formulary status.  

netFormulary